Compare · MRNA vs NMRA
MRNA vs NMRA
Side-by-side comparison of Moderna Inc. (MRNA) and Neumora Therapeutics Inc. (NMRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and NMRA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $21.45B, about 77.7x NMRA ($276.1M).
- Over the past year, MRNA is up 59.0% and NMRA is down 34.6% - MRNA leads by 93.6 points.
- MRNA has hit the wire 11 times in the past 4 weeks while NMRA has been quiet.
- MRNA has more recent analyst coverage (25 ratings vs 23 for NMRA).
- Company
- Moderna Inc.
- Neumora Therapeutics Inc.
- Price
- $54.08-5.13%
- $1.49-3.87%
- Market cap
- $21.45B
- $276.1M
- 1M return
- -10.38%
- +2.05%
- 1Y return
- +59.00%
- -34.65%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2023
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 23
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest MRNA
- Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.
- President Hoge Stephen exercised 53,336 shares at a strike of $19.15 and sold $3,605,514 worth of shares (53,336 units at $67.60) as part of a pre-agreed trading plan (SEC Form 4)
- Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
- SEC Form 4 filed by Director Mcdonnell Michael R.
- SEC Form 3 filed by new insider Mcdonnell Michael R.
- Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Moderna Appoints Michael McDonnell to Board of Directors
- SEC Form 4 filed by Chief Commercial Officer Banque Soria Ester
- Chief Financial Officer Mock James M converted options into 1,452 shares and covered exercise/tax liability with 703 shares, increasing direct ownership by 1% to 66,436 units (SEC Form 4) to satisfy withholding tax
Latest NMRA
- H.C. Wainwright reiterated coverage on Neumora Therapeutics with a new price target
- Needham reiterated coverage on Neumora Therapeutics with a new price target
- Neumora Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Costs Associated with Exit or Disposal Activities
- Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update
- SEC Form 4 filed by Director Burow Kristina
- SEC Form 4 filed by Director Fust Matthew K
- SEC Form 4 filed by Director Piacquad David
- SEC Form 4 filed by Director Halawa Alaa
- SEC Form 4 filed by Director Ho Maykin
- SEC Form 8-K filed by Neumora Therapeutics Inc.